The risk of amyloid related imaging abnormalities (ARIA) with FDA-approved anti-amyloid monoclonal antibodies: A systematic review and meta-analysis

Key Points

• Amyloid-related imaging abnormalities were found to increase in patients treated with monoclonal antibodies.
• The meta-analysis reviewed multiple studies, indicating a 40% increase in imaging abnormalities associated with treatment.
• Systematic review methods ensured thorough analysis across various trials, assessing safety implications.
• Findings highlight the need for careful monitoring of patients receiving anti-amyloid treatments for potential imaging risks.